<DOC>
	<DOCNO>NCT01077258</DOCNO>
	<brief_summary>Observation safety , tolerability effectiveness adalimumab ( Humira ) therapy large patient collective everyday clinical condition 2 year .</brief_summary>
	<brief_title>Efficacy Safety Adalimumab Patients With Rheumatoid Arthritis Routine Clinical Practice</brief_title>
	<detailed_description>Patients rheumatoid arthritis start treatment adalimumab normal clinical set accord product label document . The follow-up observation period 2 year focus safety information maintenance efficacy normal clinical setting . Follow-up participant via regular office visit interval determine routine clinical practice recommend national guideline .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Moderate severe active rheumatoid arthritis adult insufficient response diseasemodifying antirheumatic drug , include methotrexate Moderate severe active rheumatoid arthritis adult treat methotrexate . In case incompatibility methotrexate , Humira use monotherapy Hypersensitivity drug one ingredient Active tuberculosis severe infection ( e.g . sepsis opportunistic infection ) Moderate severe cardiac insufficiency</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Safety</keyword>
	<keyword>Long-term observation</keyword>
	<keyword>Routine Clinical Setting</keyword>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>Effectiveness</keyword>
</DOC>